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The oxidation of methionine residues in proteins occurs during oxidative stress and can
lead to an alteration in protein function. The enzyme methionine sulfoxide reductase
(Msr) reverses this modiﬁcation. Here, we characterise the mammalian enzyme Msr B3.
There are two splice variants of this enzyme that differ only in their N-terminal signal
sequence, which directs the protein to either the endoplasmic reticulum (ER) or mito-
chondria. We demonstrate here that the enzyme can complement a bacterial strain,
which is dependent on methionine sulfoxide reduction for growth, that the puriﬁed
recombinant protein is enzymatically active showing stereospeciﬁcity towards R-methio-
nine sulfoxide, and identify the active site and two resolving cysteine residues. The
enzyme is efﬁciently recycled by thioredoxin only in the presence of both resolving cyst-
eine residues. These results show that for this isoform of Msrs, the reduction cycle most
likely proceeds through a three-step process. This involves an initial sulfenylation of the
active site thiol followed by the formation of an intrachain disulﬁde with a resolving thiol
group and completed by the reduction of this disulﬁde by a thioredoxin-like protein to
regenerate the active site thiol. Interestingly, the enzyme can also act as an oxidase
catalysing the stereospeciﬁc formation of R-methionine sulfoxide. This result has
important implications for the role of this enzyme in the reversible modiﬁcation of ER and
mitochondrial proteins.
Introduction
Both cysteine and methionine residues in proteins are susceptible to oxidation by reactive oxygen
species [1]. This oxidation can lead to an alteration of protein function or to a signalling event result-
ing in a change in gene expression [2]. The cell has many pathways that can reverse these side chain
modiﬁcations that involve either the glutathione or thioredoxin pathways [3,4]. These pathways can
act directly to reduce modiﬁed thiols or can act indirectly through enzymes called methionine sulfox-
ide reductases (Msr) to reduce modiﬁed methionine [5].
In mammalian cells, there are up to four known isoforms and two splice variants of the enzyme
that differ in their cellular location and their stereospeciﬁcity [5]. Since the non-enzymatic oxidation
of methionine by ROS results in the formation of a diastereomeric mixture of methionine S-sulfoxide
and methionine R-sulfoxide [6], two enzymes are required to catalyse complete reduction. The MsrA
enzymes speciﬁcally reduce the S-epimer, whereas the MsrB enzymes reduce the R-epimer [7]. There
are two main splice variants of MsrA in mammalian cells that differ at their N-terminal region: one
having a mitochondrial targeting signal and localising to this organelle and the other being localised
to the cytosol and the nucleus [8]. There are three known MsrB enzymes. MsrB1 is localised to the
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cytosol and is the only isoform that contains a selenocysteine at its active site. MsrB2 is localised to mitochon-
dria, whereas MsrB3 exists as two main splice variants A and B, containing either a signal sequence targeting
the protein to the ER or to the mitochondria, respectively [9]. Cleavage of either signal sequence results in an
identical mature protein. As there is only one Msr known to be localised to the ER, MsrB3A, its stereospeciﬁ-
city suggests that only half the non-enzymatically oxidised methionine residues in proteins present in the ER
are reduced or that there is an epimerase capable of converting the S- into the R-epimer. In contrast with
MsrA, all the MsrB enzymes are zinc-binding proteins. The zinc centre seems to play a structural rather than
catalytic role [10].
Previous work on puriﬁed recombinant MsrB3 has revealed its ability to reduce methionine sulfoxide with
apparent speciﬁcity for the R-epimer [9–11]. The ﬁrst step in the Msr reaction is the formation of a sulfenic
acid intermediate on the catalytic Cys of the enzyme and the concomitant release of reduced methionine.
Characterisation of the role of individual cysteines in the enzymatic process for MsrB3 has suggested that the
mechanism of recycling involves the direct reduction of this active site thiol by a thioredoxin domain-
containing protein [11]. This contrasts with MsrB1 which acts via a two-step process involving an internal
resolving cysteine that reduces the sulfenylated active site thiol forming a disulﬁde which is reduced further by
thioredoxin [10], but is consistent with the proposed mechanism for MsrB2 which also does not involve a
resolving cysteine [12].
Most of the MsrA enzymes have a single resolving cysteine and recycle the active site via a two-step mechan-
ism. However, a subclass of MsrA enzymes have two resolving cysteines which are thought to act via a three-
step process involving disulﬁde exchange which results in the formation of an internal disulﬁde bond
between the resolving cysteines that is reduced by thioredoxin or low molecular mass thiols [13–15]. This par-
ticular subclass of MsrA enzymes acts as a stereospeciﬁc reductase, but has also been shown to catalyse the
stereospeciﬁc oxidation of methionine, a reaction that does not require thioredoxin and results in exclusively
the S-epimer [16,17].
The functional role of MsrB3 in cells is poorly deﬁned. The poor growth on methionine R-sulfoxide pheno-
type demonstrated by a yeast strain carrying both MsrA and MsrB deletions was complemented by mouse
MsrB3, but only when this protein was targeted to the mitochondria [9]. This suggests that when mouse
MsrB3 is expressed in the yeast ER, it is either non-functional or unable to reduce free methionine sulfoxide
for further metabolism. However, depletion of the ER-localised MsrB3A in mammalian cells leads to ER stress,
whereas overexpression of MsrB3A is protective [18]. These results suggest an important role for MsrB3A in
preventing the accumulation of misfolded proteins. Functionally null mutants of the MsrB3 gene also lead to
deafness, though whether this is caused by lack of ER or mitochondrial function is unclear [19,20].
To provide further insight into the function and enzymatic mechanism of MsrB3A, we characterised the
properties of the recombinant protein against a model substrate using different electron donors. By carrying
out selective mutagenesis of cysteine residues, we show that the enzyme is most efﬁciently recycled by a three-
step process requiring two potential resolving cysteine residues. These results contrast with previous interpreta-
tions and suggest that resolving cysteine(s) are required for mammalian MsrB1 and MsrB3. In addition, we
demonstrate that MsrB3 is able to act as an oxidase suggesting a role for methionine oxidation in the regulation
of ER protein function.
Experimental procedures
Reagents and antibodies
Most reagents were purchased from Sigma–Aldrich (Dorset, U.K.), with some enzymes from Promega
(Southampton, U.K.) unless otherwise stated. Rabbit monoclonal anti-MsrB3 antibody was purchased from
Abcam (Cambridge, U.K.) and mouse anti-His antibody was purchased from Proteintech Europe (Manchester
U.K.). Human thioredoxin (trx) and thioredoxin reductase (trxR) used in enzyme assays were purchased from
IMCO (Stockholm, Sweden).
Synthesis of dabsylated methionine and dabsylated methionine sulfoxides
Adapting a previous procedure [21], N-dabsyl-L-methionine was synthesised as follows:
4-(4-dimethylaminophenylazo)benzenesulfonyl chloride (dabsyl chloride) (100 mg, 0.31 mmol, 1.0 eq) was
added to a solution of L-methionine (55 mg, 0.37 mmol, 1.2 eq) and sodium bicarbonate (156 mg, 0.85 mmol,
6.0 eq) in acetone (40 ml) and water (5 ml). The solution was stirred at RT for 2 h and then the acetone was
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removed under vacuum. The solution was slowly acidiﬁed and the resulting precipitate ﬁltered off and washed
with water. The solid was puriﬁed by automated chromatography on a Biotage Isolera using a 10 g SNAP ultra-
cartridge and eluting with CH2Cl2 : MeOH (100 : 0 to 91 : 9) to give the N-dabsyl-L-methionine as an orange
solid. 1H NMR (400 MHz: CDCl3) δH: 1.80–1.89 (1H, m, CHCHAHB), 1.99–2.06 (1H, m, CHCHAHB), 2.02
(3H, s, SCH3), 2.44–2.58 (2H, m, SCH2), 3.10 (6H, s, NCH3), 4.08–4.13 (1H, m, CH), 5.57 (1H, d, J = 9.1 Hz,
NH), 6.73 (2H, d, J = 9.3 Hz, ArH), 7.83–7.91 (6H, m, ArH). A 1 : 1 mixture of N-dabsyl-L-methionine
R-sulfoxide and N-dabsyl-L-methionine S-sulfoxide was synthesised using a similar procedure, but with an epi-
meric mixture of L-methionine R-sulfoxide and L-methionine S-sulfoxide as the starting material and using a
gradient of CH2Cl2 : MeOH (100 : 0 to 75 : 25) in the puriﬁcation.
1H NMR (400 MHz: CD3OD) δH: 2.00–2.10
(1HR&S, m, CHCHAHB), 2.24–2.31 (1H
R&S, m, CHCHAHB), 2.63 [3H
R orS, s, S(O)CH3], 2.64 [3H
R or S, s, S(O)
CH3], 2.79–2.89 [1H
R&S, m, S(O)CHAHB], 2.92–3.02 [1H
R&S, m, S(O)CHAHB], 3.14 (6H
R&S, s, NCH3), 4.08
(1HR&S, dd, J = 9.1, 4.6 Hz, CHNH), 6.87 (2HR&S, d, J = 9.2 Hz, ArH), 7.89 (2HR&S, d, J = 9.1 Hz, ArH), 7.90–
7.94 (2HR&S, m, ArH), 7.97–8.00 (2HR&S, m, ArH).
DNA constructs
Human MsrB3 DNA constructs, lacking any N-terminal signal sequence, containing a GST tag at C-terminus
were synthesised by GenScript (New Jersey, U.S.A.). Mutagenesis was performed as described previously [22]
using GST-tagged MsrB3A as a template.
MsrB3A complementation assay
Human MsrB3, lacking any signal sequence, was cloned into pAG177 vector, which allows expression from the
tac promoter. The construct was transformed into Escherichia coli strain JB590, a methionine auxotroph, which
lacks the genes encoding MsrA, MsrB, MsrC and BisC, and therefore is not able to use methionine sulfoxide as
the only source of methionine [23]. This transformed strain and the JB590 strain containing an empty pAG177
vector were grown on M63 medium agar plates containing 20 mg/ml Met-O (mixture of both epimers), 10 mM
IPTG and 200 mg/ml ampicillin for 48 h at 37°C.
Preparation of puriﬁed proteins
All MsrB3 proteins were expressed and puriﬁed using E. coli BL21-DE3. GST-MsrB3 was expressed for 16 h at
18°C in the presence of 0.2 mM IPTG. Cells were disrupted by two passes through a chilled French pressure
cell at 12 000 psi. The resulting crude extract was centrifuged for 45 min at 30 000×g and 4°C. Cells were lysed
and GST-MsrB3 bound to GSH-Sepharose (GE Healthcare, Buckinghamshire, U.K.). MsrB3 was eluted by
on-column cleavage with precision protease (GE Healthcare) in accordance with the manufacturer’s instruc-
tions. Proteins were reduced by incubation with 5 mM DTT for 15 min at room temperature, then DTT
removed by a Superdex 200 gel ﬁltration column (GE Healthcare). The puriﬁcation of His-tagged trx and its
mutants has been described previously [24]. Each protein was quantiﬁed using the relevant 280 nm absorption
extinction coefﬁcient.
MsrA from E. coli containing a C-terminal His-tag was expressed and puriﬁed as described previously [25]
with some modiﬁcations. Brieﬂy, BL21 (DE3) cells harbouring the pET21MsrA vector were grown at 37°C and
induced with 1 mM IPTG for 3 h. Cells were then pelleted, resuspended in buffer A (50 mM NaPi, pH 8.0,
containing 300 mM NaCl) and disrupted by two passes through a chilled French pressure cell at 12 000 psi.
The resulting crude extract was centrifuged for 45 min at 30 000×g and 4°C. The supernatant was loaded on a
5 ml Histrap FF column (GE Healthcare) previously equilibrated with buffer A and was eluted by applying a
linear gradient of imidazole (from 0 to 300 mM) in buffer A. Selected elution fractions containing MsrA-His
were pooled, concentrated using a 5 kDa cut-off Vivaspin 15 (Sartorius) device and buffer-exchanged on a
PD-10 column (GE Healthcare) equilibrated with 50 mM NaPi (pH 8.0) and 150 mM NaCl.
Assay for MsrB3 reductase activity
The reaction mixture (200 ml) contained 20 mM Tris–HCl buffer, pH 7.5, containing 150 mM NaCl, 500 mM
dabsyl-methionine sulfoxide, 20 mM MsrB3A protein and 10 mM DTT or a trx recycling system (5 mM trx,
65 nM trxR and 5 mM NADPH). The reaction was carried out at 37°C for various lengths of time before being
loaded onto a C18 column (25 cm Apex ODS 5 m, Jones Chromatography) equilibrated in 100 mM sodium
acetate (pH 6) and 30% acetonitrile. An Akta Micro-Chromatography system was used controlled by the
Unicorn software (v.5.2). The sample was eluted using a linear gradient (from 30 to 70% over three column
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volumes) of acetonitrile and the dabsyl derivatives were monitored by absorbance at 460 nm. The fraction of
reduced product was calculated by dividing the amount of dabsylated methionine produced by the total
amount of dabsyl-methionine R-sulfoxide and dabsyl-methionine at each time point.
Assay for MsrB3 oxidase activity
Wild-type or mutant MsrB3 was ﬁrst oxidised by incubation with a 20-fold molar excess of methionine sulfox-
ide for 30 min at 37°C. The excess methionine sulfoxide was then removed by passing through a desalting spin
column twice. Oxidised MsrB3 (250 mM) was then incubated with an equimolar concentration of dabsyl-
methionine for 12 h at 37°C. Product formation was then evaluated by RP-HPLC as described above.
Immunoblotting
Samples containing 20 mM Tris–HCl buffer (pH 7.5), 150 mM NaCl, 500 mM methionine sulfoxide, 10 mM
MsrB3 and/or trx proteins were incubated at 37°C for 1 h before being separated on a 15% SDS–PAGE gel and
then proteins being transferred to a nitrocellulose membrane (GE Healthcare). Non-speciﬁc binding was
blocked using 5% (w/v) non-fat dried skimmed milk in Tween/Tris-buffered saline (TTBS) [50 mM Tris–HCl
buffer, pH 7.5, containing 150 mM NaCl and 0.1% (v/v) Tween 20]. The same membrane was incubated with
both primary antibodies for 16 h at 4°C in TTBS. The ﬂuorescent secondary antibodies were diluted 1 : 5000 in
TTBS and incubation was performed in a light-shielded box for 45 min at room temperature. For Msr3B anti-
body, the anti-rabbit secondary antibody was conjugated to a probe that emits at 700 nm (red), whereas for trx
the anti-mouse secondary is conjugated to a probe that emits at 800 nm (green). Speciﬁc proteins were visua-
lised using an Odyssey LI-COR Sa imaging system on two independent channels at 700 and 800 nm.
Results
Expression and characterisation of human MsrB3
To evaluate the enzymatic activity of MsrB3, we ﬁrst prepared recombinant mature protein lacking any signal
sequence. The protein was expressed in E. coli as a fusion protein with GST which was subsequently cleaved
after puriﬁcation to yield the 21 kDa MsrB3 protein (Figure 1A). The addition of a mixture of isomers of dab-
sylated methionine sulfoxide to the enzyme in the presence of DTT led to the production of methionine
(Figure 1B,C). The product was separated from the reactant by RP-HPLC, which also separated the substrate
into two peaks presumably representing the R- and S-epimers. Only the second of these two peaks was reduced
by MsrB3 demonstrating stereospeciﬁcity in its enzymatic reaction. To determine which isomer was reduced by
MsrB3, we puriﬁed E. coli MsrA which is known to reduce methionine S-sulfoxide. We then carried our
enzymatic assay with MsrA or B3 alone or together (Figure 1D). MsrA reduced the ﬁrst but not the second
substrate peak, whereas the combination of both enzymes reduced both peaks. These results demonstrate that
MsrB3 is enzymatically active towards methionine sulfoxide and speciﬁcally reduces the R-epimer.
We evaluated whether MsrB3 was active in vivo by determining its ability to complement an E. coli strain
that is depleted of all endogenous Msrs and is auxotrophic for methionine. We have previously shown that
when methionine sulfoxide is provided as a mixture of isomers in the medium, this strain is unable to grow as
it cannot convert methionine sulfoxide into methionine. When human MsrB3 was expressed in this strain, it
was now able to grow on medium containing methionine sulfoxide. These results demonstrate that MsrB3 is
able to function in vivo to complement a bacterial strain deﬁcient in endogenous Msr.
Deﬁning the catalytically important thiols
An alignment plot of the three human MsrB proteins illustrates that there are many highly conserved cysteines
(Figure 2A,B). These include the putative active site thiol (C126 — MsrB3 mature sequence numbering) and
two CXXC motifs that constitute a zinc-binding site. The resolving cysteine in MsrB1 is located within the
N-terminal region. While this cysteine residue is conserved in MsrB2 and MsrB3 (C09), it is not thought to
carry out a role as a resolving cysteine in these enzymes [11]. MsrB3 contains an additional non-conserved
cysteine (C03) close to its N-terminus which has the potential to act as a resolving cysteine. To evaluate a
potential role for C03 and C09 in resolving the active site sulfenylated thiol, we mutated these residues to
alanine individually or together and determined the effect on enzymatic activity using DTT or thioredoxin as
electron donors (Figure 2C,D). We also veriﬁed that C126 is the active site thiol as mutating this residue to
alanine resulted in no enzymatic activity. Single mutation of C03 or C09 to alanine resulted in a dramatic
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reduction of activity when thioredoxin was used as an electron donor. When both residues were mutated,
almost no activity was recorded indicating that one or other of these two cysteines is required for optimal activ-
ity in the presence of thioredoxin. Wild-type level of activity for the single and double C03 and C09 mutants
was recorded when DTT was used as the electron donor, indicating that these mutations did not effect the
ability of the enzyme to catalyse methionine sulfoxide reduction suggesting that they still folded correctly.
Taken together, the results with these mutants strongly suggest that either C03 or C09 can act as a resolving
thiol and that thioredoxin can only directly reduce the sulfenylated active site thiol inefﬁciently. For maximal
activity with thioredoxin, both C03 and C09 need to be present, suggesting that the preferred mechanism is via
an internal disulﬁde between these two cysteines.
Direct reduction of MsrB3 by thioredoxin mediated by resolving cysteines
To determine the ability of thioredoxin to directly reduce the thiol groups within MsbB3, we made use of a
substrate-trap mutant of thioredoxin. If the second cysteine within the CXXC catalytic motif of thioredoxin is
mutated to serine, the resulting CXXS (CS) can initiate catalysis by the reduction of the disulﬁde in oxidised
MsrB3 to form a mixed disulﬁde, but cannot resolve this mixed disulﬁde with the result being a stabilised
covalent link between the enzyme and the substrate [26] (Figure 3A). When either wild-type or CS-thioredoxin
was incubated with MsrB3 in the presence of methionine sulfoxide, mixed disulﬁdes were formed that
migrated at ∼40 kDa (Figure 3B–F). While mixed disulﬁdes formed with wild-type thioredoxin, they were
more prominent with the CS mutant. The mixed disulﬁde migrated between MsrB3 and thioredoxin dimers
Figure 1. Characterisation of the reductase activity of MsrB3.
(A) Partially puriﬁed MsrB3 after expression in E. coli was separated by SDS–PAGE before Coomassie blue staining. (B) Activity
of MsrB3 was assayed in the presence of a mixture of methionine R- and S-methionine sulfoxide and DTT. Incubation was
carried out for the times indicated prior to separation of the product and reactant by RP-HPLC using a linear gradient from
30% to 70% acetonitrile. Dabsyl-methionine (M) (retention time ∼38.5 min) was separated from methionine sulfoxide (M-OH S/
R) (retention time between 24 and 25 min). Dabsylated molecules were detected by following absorption at 460 nm. The same
experiment was carried out at least three times with similar results. (C) Quantiﬁcation of the time course carried out in (B) with
the fraction reduced plotted against time. (D) RP-HPLC of reactions carried out in the presence of dabsyl-methionine sulfoxide
and DTT in the absence (black) or presence of MsrA (red), MsrB3 (green) or MsrA with MsrB3 (blue). (E) A bacterial strain
auxotrophic for methionine was transfected with empty plasmid (left) or MsrB3-expressing plasmid (right) prior to plating on an
agar plate containing methionine sulfoxide as the sole source of methionine.
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identiﬁed by western blotting with either antibodies to MsrB3 or the His-tagged thioredoxin (indicated by
three lines in Figure 3B,C). The mixed disulﬁde was also veriﬁed by co-localisation of green and red ﬂuores-
cence resulting in a yellow colour when the western blot was visualised before splitting the channels
(Figure 3D). All mixed disulﬁdes were lost when the samples were separated following reduction of disulﬁdes
with DTT (Figure 3E–G). These results demonstrate that thioredoxin can directly reduce oxidised MsrB3 to
form a mixed disulﬁde.
Having established that thioredoxin can form a mixed disulﬁde to MsrB3, we then determined the conse-
quence of mutating the active site or resolving cysteine residues, individually or together, on mixed disulﬁde
formation (Figure 4). Mixed disulﬁdes migrating at ∼40 kDa were observed for the wild-type, single resolving
cysteine mutants (C03C and C09A) and to a much lesser extent, the double mutant. No mixed disulﬁdes
were observed to the active site cysteine mutant (C126A) despite the presence of both resolving cysteines. All
Figure 2. Identiﬁcation of the active site and resolving cysteine residues in MsrB3.
(A) Alignment plot of the human MsrB family of proteins. Identical conserved residues are in blue. Boxes depict two CXXC
motifs that are thought to be involved in zinc binding. The putative active site cysteine is indicated with an arrow below the
sequence. (B) Schematic of MsrB3 illustrating the positions of the cysteine residues. (C and D) Msr3B activity assays carried
out with either thioredoxin (trx) or DTT as an electron donor. Assays were carried out for 120 min in the absence or presence of
MsrB3 wild-type or cysteine mutants as indicated. DM: C03A, C09A double mutant. Error bars represent ± SD from three
independent experiments.
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Figure 3. Formation of a mixed disulﬁde between MsrB3 and Trx.
(A) Cartoon depicting the potential mechanism of reduction of a disulﬁde within MsrB3 by thioredoxin wild-type (WT) or a
substrate-trapping mutant of thioredoxin (CS). In both cases, the ﬁrst step of the reaction involves the formation of a mixed
disulﬁde between the enzyme and the substrate. This is resolved with the WT protein resulting in reduction of the disulﬁde in
MsrB3 and the formation of a disulﬁde in thioredoxin. As the second active site cysteine is mutated to a serine in the
substrate-trapping mutant, the mixed disulﬁde intermediate persists allowing identiﬁcation of a complex between the enzyme
and the substrate. (B–G) WT (trx WT) or mutant (trx CS) thioredoxin was incubated with MsrB3A and methionine sulfoxide at
37°C for 1 h. The mixtures were then separated on an SDS–PAGE gel in the absence (B–D) or presence (E–G) of DTT and
proteins identiﬁed by immunoblotting with anti-MsrB3 (red) (B and E) or anti-His (green) for thioredoxin (C and F). The blots
were scanned with a Licor Odyssey at 700 and 800 nm. The image was split into two channels to identify protein bands
containing MsrB3 (B and E) or thioredoxin (C and F). The image prior to channel splitting is also depicted (D and G) to illustrate
co-migration of complexes containing both MsrB3 and thioredoxin (appear as yellow bands). The migration of MsrB3 and
thioredoxin dimers (*) as well as the complex between MsrB3 and thioredoxin are indicated with three lines next to the gel
images.
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mixed disulﬁdes were lost when the samples were separated after reduction with DTT (Figure 4D–F). These
results demonstrate that the active site cysteine is required for thioredoxin to form mixed disulﬁdes and the
presence of the resolving cysteines greatly enhances their formation.
We also observed additional higher molecular mass mixed disulﬁdes between MsrB3 and thioredoxin, par-
ticularly with the resolving cysteine mutants (Figure 4A–C). These additional products are conﬁrmed as mixed
disulﬁdes as they react with both antibodies to MsrB3 and thioredoxin. As we observe mixed disulﬁdes
between either C03, C09 or C126, these additional mixed disulﬁdes are most likely to be MsrB3 with two thior-
edoxin molecules linked via C126 and either C03 or C09. Taken together, these results demonstrate that each
resolving cysteine can form a disulﬁde with the active site thiol and that either of these disulﬁdes can be a sub-
strate for thioredoxin reduction.
MsrB3 can act as a stereospeciﬁc oxidase generating the R-epimer
The oxidation of methionine by chemicals such as hydrogen peroxide generates a mixture of the S- and
R-epimers [6]. As MsrB3 is able to reduce only the R-epimer and is the only Msr within the ER, we evaluated
its ability to act as an oxidase. We prepared the enzyme containing a sulfenylated thiol at its active site as
described previously for MsrA [16] by incubating the enzyme with an excess of methionine sulfoxide. When
this oxidised enzyme was incubated with stoichiometric amounts of methionine, we detected complete conver-
sion to methionine R-sulfoxide (Figure 5). Both the wild type and the double mutant (DM) were able to cata-
lyse this conversion, whereas the C126A active site mutant was inactive. These results demonstrate that, under
the conditions used in this experiment, MsrB3 can act as a stereospeciﬁc oxidase and that this activity does not
require the resolving cysteine residues or the presence of thioredoxin.
Figure 4. Formation of mixed disulﬁdes between thioredoxin and MsrB3 cysteine mutants.
(A–F) The substrate-trapping mutant of thioredoxin was incubated with WT and various cysteine mutants of MsrB3 as indicated
and separated by SDS–PAGE either in the absence (A–C) or presence (D–F) of DTT. Immunoblotting, scanning and image
presentation is as described in Figure 3.
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Discussion
Here, we have conﬁrmed the speciﬁc reduction of methionine R-sulfoxide by MsrB3 and shown that the
enzyme mechanism most likely involves a three-stage process as outlined (Figure 6). The essential difference
from the previous mechanism suggested for this enzyme [11] is the presence of two resolving thiols that could
work together or independently. Partial loss of activity when either of these two thiols were mutated suggests
that either could function to directly reduce the active site sulfenylated thiol and that the presence of both
thiols is required for full activity when thioredoxin is the electron donor. Removal of both thiols did not com-
pletely remove activity, suggesting that thioredoxin can directly reduce the active site thiol albeit inefﬁciently.
This is supported by the ability to form mixed disulﬁdes between the MsrB3 active site thiol and thioredoxin.
However, the greater activity when the resolving thiols are present along with the more efﬁcient formation of
mixed disulﬁdes to thioredoxin suggests that the preferred mechanism is via a resolving thiol.
As Msr3BA is localised to the ER lumen, thioredoxin will not be its physiological reductant. However, there
are several thioredoxin domain-containing proteins in the ER including members of the protein disulﬁde isom-
erase (PDI) family. Strong candidates for PDIs which could act as a reductant include ERdj5 [27] or
TXNDC11 [28], which each have relatively low reduction potentials. To complete the enzymatic cycle would
require a thioredoxin reductase or an equivalent system within the ER lumen. No such enzyme has been identi-
ﬁed to date, suggesting the requirement for an alternative source of reducing equivalents [29]. Possibilities
include reduction by glutathione or the transfer of reducing equivalents from the thioredoxin pathway in the
cytosol across the ER membrane. Such a pathway has been suggested recently to allow the reduction of non-
native disulﬁdes formed in some proteins during their normal folding pathway [30,31].
The ability of MsrB3 to act as a stereospeciﬁc oxidase forming methionine R-sulfoxide mirrors the ability of
some MsrA enzymes to form methionine S-sulfoxide. While the oxidation reaction is much slower than reduc-
tion, it has been argued that under physiological conditions, the reaction may well be signiﬁcant [14,17]. Such
an oxidase activity is reliant upon the absence of rapid recycling of the sulfenylated active site thiol. Using a
kinetic approach with MsrA, it was demonstrated that once the internal disulﬁde bond is formed between the
resolving cysteines, then the rate of sulfenylation of the active site thiol is higher than that of reduction of the
internal disulﬁde by thioredoxin [17]. This would allow the sulfenylated active site to catalyse the oxidation of
its substrate. In regard to MsrB3, this would mean that once the disulﬁde between C03 and C09 had formed,
C126 could become sulfenylated for sufﬁcient time to allow oxidation. In addition, the absence of a robust
Figure 5. MsrB3 can act as a stereospeciﬁc oxidase.
Msr3B was initially incubated with methionine sulfoxide in the absence of an electron donor to sulfenylate the active site thiol.
After removal of methionine sulfoxide, the enzyme was incubated with dabsyl-methionine for 12 h at 37°C before RP-HPLC.
The elution proﬁles of dabsyl-methionine (grey) and a mixture of dabsyl-methionine S- and R- sulfoxide (red) are shown to
illustrate the retention times for these molecules. The elution proﬁles of reactants of dabsyl-methionine with WT MsrB3 (blue),
MsrB3 DM (green) and MsrB3 C126A (cyan) are shown. No reaction occurs with MsrB3 C126A, but stoichiometric conversion
of methionine into methionine R-sulfoxide occurs with both MsrB3 WT and DM.
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thioredoxin reductase pathway in the ER may slow down the recycling pathway thereby prolonging the sulfeny-
lated active site intermediate. Other ER enzyme, such as peroxiredoxin IV, requires reduction of a disulﬁde to
maintain activity, and this reductive step has been demonstrated to be less efﬁcient within the ER than the
cytosol [32].
The physiological role of MsrB3A remains unknown due to the absence of data on the role and extent of
methionine oxidation within the ER or the potential substrates for this enzyme. It is known that MsrB3A deﬁ-
ciency causes ER stress as well as an increased sensitivity of cancer cells to apoptosis [18,33]. These observa-
tions would suggest an important physiological role for methionine sulfoxide reduction in the ER to alleviate
stress. The potential oxidase activity of MsrB3 suggests an alternative role in the regulation of protein function
by reversible modiﬁcation of methionine.
Abbreviations
DM, double mutant; ER, endoplasmic reticulum; Msr, methionine sulfoxide reductases; PDI, protein disulﬁde
isomerase; Trx, thioredoxin; trxR, thioredoxin reductase; TTBS, Tween/Tris-buffered saline.
Author Contribution
N.J.B. and Z.C. designed the experiments and wrote the paper. R.C.H., J.-F.C. and A.G. provided reagents and
ideas for the work. Z.C., L.M., O.H., M.S., S.T.C. and A.D.A. performed the experiments.
Funding
The work was funded by the Biochemistry and Biological Sciences Research Council (BBSRC) [grant no.
BB/K501864/1 to N.J.B.], a Wellcome Trust grant [110158/Z/15/Z] to R.C.H. and by grants from Fund for
Figure 6. Overall reaction sequence for MsrB3.
Cartoon depicting a potential reaction sequence for MsrB3 (adapted from ref. [17]). Fully reduced enzyme (A) reacts with
methionine sulfoxide (Met-O) to form methionine and in the process the active site cysteine 126 becomes sulfenylated (B). This
sulfenylated thiol can then be reduced by either cys03 or cys09 forming a transient disulﬁde between the active site and the
resolving thiol (Ci or Cii). After disulﬁde exchange, an internal disulﬁde is formed between cys 03 and 09 (D). A second
molecule of methionine sulfoxide can then react with the active site cysteine to form E. The internal disulﬁde can then be
reduced to regenerate (B).
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).836
Biochemical Journal (2018) 475 827–838
https://doi.org/10.1042/BCJ20170929
Strategic Fundamental Research (FRFS-WELBIO) and the European Research Council [(FP7/2007–2013),
ERC independent researcher starting grant 282335 — Sulfenic] to J.-F.C. J.-F.C. is ‘Directeur de Recherche’
and A.G. is ‘Chargée de Recherche’ of the Fonds de la Recherche Scientiﬁque FRS-FNRS.
Competing Interests
The Authors declare that there are no competing interests associated with the manuscript.
References
1 Stadtman, E.R. and Levine, R.L. (2003) Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 25,
207–218 https://doi.org/10.1007/s00726-003-0011-2
2 Kaya, A., Lee, B.C. and Gladyshev, V.N. (2015) Regulation of protein function by reversible methionine oxidation and the role of selenoprotein MsrB1.
Antioxid. Redox Signal. 23, 814–822 https://doi.org/10.1089/ars.2015.6385
3 Schafer, F.Q. and Buettner, G.R. (2001) Redox environment of the cell as viewed through the redox state of the glutathione disulﬁde/glutathione couple.
Free Radic. Biol. Med. 30, 1191–1212 https://doi.org/10.1016/S0891-5849(01)00480-4
4 Arnér, E.S. (2009) Focus on mammalian thioredoxin reductases — important selenoproteins with versatile functions. Biochim. Biophys. Acta, Gen. Subj.
1790, 495–526 https://doi.org/10.1016/j.bbagen.2009.01.014
5 Kim, H.-Y. and Gladyshev, V.N. (2007) Methionine sulfoxide reductases: selenoprotein forms and roles in antioxidant protein repair in mammals.
Biochem. J. 407, 321–329 https://doi.org/10.1042/BJ20070929
6 Toennies, G. and Kolb, J.J. (1939) Methionine studies II. DL-methionine sulfoxide. J. Biol. Chem. 128, 399–405
7 Weissbach, H., Etienne, F., Hoshi, T., Heinemann, S.H., Lowther, W.T., Matthews, B. et al. (2002) Peptide methionine sulfoxide reductase: structure,
mechanism of action, and biological function. Arch. Biochem. Biophys. 397, 172–178 https://doi.org/10.1006/abbi.2001.2664
8 Vougier, S., Mary, J. and Friguet, B. (2003) Subcellular localization of methionine sulphoxide reductase A (MsrA): evidence for mitochondrial and
cytosolic isoforms in rat liver cells. Biochem. J. 373, 531–537 https://doi.org/10.1042/bj20030443
9 Kim, H.-Y. and Gladyshev, V.N. (2004) Methionine sulfoxide reduction in mammals: characterization of methionine-R-sulfoxide reductases. Mol. Biol. Cell
15, 1055–1064 https://doi.org/10.1091/mbc.E03-08-0629
10 Kumar, R.A., Koc, A., Cerny, R.L. and Gladyshev, V.N. (2002) Reaction mechanism, evolutionary analysis, and role of zinc in Drosophila
methionine-R-sulfoxide reductase. J. Biol. Chem. 277, 37527–37535 https://doi.org/10.1074/jbc.M203496200
11 Kim, H.-Y. and Gladyshev, V.N. (2005) Different catalytic mechanisms in mammalian selenocysteine- and cysteine-containing methionine-R-sulfoxide
reductases. PLoS Biol. 3, e375 https://doi.org/10.1371/journal.pbio.0030375
12 Aachmann, F.L., Kwak, G.-H., Del Conte, R., Kim, H.-Y., Gladyshev, V.N. and Dikiy, A. (2011) Structural and biochemical analysis of mammalian
methionine sulfoxide reductase B2. Proteins: Struct., Funct., Bioinf. 79, 3123–3131 https://doi.org/10.1002/prot.23141
13 Tossounian, M.-A., Pedre, B., Wahni, K., Erdogan, H., Vertommen, D., Van Molle, I. et al. (2015) Corynebacterium diphtheriae methionine sulfoxide
reductase a exploits a unique mycothiol redox relay mechanism. J. Biol. Chem. 290, 11365–11375 https://doi.org/10.1074/jbc.M114.632596
14 Boschi-Muller, S. and Branlant, G. (2014) Methionine sulfoxide reductase: chemistry, substrate binding, recycling process and oxidase activity. Bioorg.
Chem. 57, 222–230 https://doi.org/10.1016/j.bioorg.2014.07.002
15 Boschi-Muller, S., Azza, S., Sanglier-Cianferani, S., Talfournier, F., Van Dorsselear, A. and Branlant, G. (2000) A sulfenic acid enzyme intermediate is
involved in the catalytic mechanism of peptide methionine sulfoxide reductase from Escherichia coli. J. Biol. Chem. 275, 35908–35913 https://doi.org/
10.1074/jbc.M006137200
16 Lim, J.C., You, Z., Kim, G. and Levine, R.L. (2011) Methionine sulfoxide reductase A is a stereospeciﬁc methionine oxidase. Proc. Natl Acad. Sci. U.S.A.
108, 10472–10477 https://doi.org/10.1073/pnas.1101275108
17 Kriznik, A., Boschi-Muller, S. and Branlant, G. (2014) Kinetic evidence that methionine sulfoxide reductase A can reveal its oxidase activity in the
presence of thioredoxin. Arch. Biochem. Biophys. 548, 54–59 https://doi.org/10.1016/j.abb.2014.03.002
18 Kwak, G.-H., Lim, D.-H., Han, J.-Y., Lee, Y.S. and Kim, H.-Y. (2012) Methionine sulfoxide reductase B3 protects from endoplasmic reticulum stress in
Drosophila and in mammalian cells. Biochem. Biophys. Res. Commun. 420, 130–135 https://doi.org/10.1016/j.bbrc.2012.02.128
19 Ahmed, Z.M., Yousaf, R., Lee, B.C., Khan, S.N., Lee, S., Lee, K. et al. (2011) Functional null mutations of MSRB3 encoding methionine sulfoxide
reductase are associated with human deafness DFNB74. Am. J. Hum. Genet. 88, 19–29 https://doi.org/10.1016/j.ajhg.2010.11.010
20 Kim, M.-A., Cho, H.-J., Bae, S.-H., Lee, B., Oh, S.-K., Kwon, T.-J. et al. (2016) Methionine sulfoxide reductase B3-targeted in utero gene therapy
rescues hearing function in a mouse model of congenital sensorineural hearing loss. Antioxid. Redox Signal. 24, 590–602 https://doi.org/10.1089/ars.
2015.6442
21 Minetti, G., Balduini, C. and Brovelli, A. (1994) Reduction of DABS-L-methionine-DL-sulfoxide by protein methionine sulfoxide reductase from
polymorphonuclear leukocytes: stereospeciﬁcity towards the l-sulfoxide. Ital. J. Biochem. 43, 273–283 PMID:7759220
22 Hemsley, A., Arnheim, N., Toney, M.D., Cortopassi, G. and Galas, D.J. (1989) A simple method for site-directed mutagenesis using the polymerase
chain reaction. Nucleic Acids Res. 17, 6545–6551 https://doi.org/10.1093/nar/17.16.6545
23 Gennaris, A., Ezraty, B., Henry, C., Agrebi, R., Vergnes, A., Oheix, E. et al. (2015) Repairing oxidized proteins in the bacterial envelope using respiratory
chain electrons. Nature 528, 409–412 https://doi.org/10.1038/nature15764
24 Tavender, T.J. and Bulleid, N.J. (2010) Peroxiredoxin IV protects cells from oxidative stress by removing H2O2 produced during disulphide formation.
J. Cell Sci. 123, 2672–2679 https://doi.org/10.1242/jcs.067843
25 Grimaud, R., Ezraty, B., Mitchell, J.K., Laﬁtte, D., Briand, C., Derrick, P.J. et al. (2001) Repair of oxidized proteins. Identiﬁcation of a new methionine
sulfoxide reductase. J. Biol. Chem. 276, 48915–48920 https://doi.org/10.1074/jbc.M105509200
26 Schwertassek, U., Balmer, Y., Gutscher, M., Weingarten, L., Preuss, M., Engelhard, J. et al. (2007) Selective redox regulation of cytokine receptor
signaling by extracellular thioredoxin-1. EMBO J. 26, 3086–3097 https://doi.org/10.1038/sj.emboj.7601746
27 Ushioda, R. and Nagata, K. (2011) The endoplasmic reticulum-associated degradation and disulﬁde reductase ERdj5. Methods Enzymol. 490, 235–258
https://doi.org/10.1016/B978-0-12-385114-7.00014-3
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 837
Biochemical Journal (2018) 475 827–838
https://doi.org/10.1042/BCJ20170929
28 Timms, R.T., Menzies, S.A., Tchasovnikarova, I.A., Christensen, L.C., Williamson, J.C., Antrobus, R. et al. (2016) Genetic dissection of mammalian
ERAD through comparative haploid and CRISPR forward genetic screens. Nat. Commun. 7, 11786 https://doi.org/10.1038/ncomms11786
29 Bulleid, N.J. and van Lith, M. (2014) Redox regulation in the endoplasmic reticulum. Biochem. Soc. Trans. 42, 905–908 https://doi.org/10.1042/
BST20140065
30 Poet, G.J., Oka, O.B.V., van Lith, M., Cao, Z., Robinson, P.J., Pringle, M.A. et al. (2017) Cytosolic thioredoxin reductase 1 is required for correct
disulﬁde formation in the ER. EMBO J. 36, 693–702 https://doi.org/10.15252/embj.201695336
31 Jansens, A., van Duijn, E. and Braakman, I. (2002) Coordinated nonvectorial folding in a newly synthesized multidomain protein. Science 298,
2401–2403 https://doi.org/10.1126/science.1078376
32 Cao, Z., Subramaniam, S. and Bulleid, N.J. (2014) Lack of an efﬁcient endoplasmic reticulum-localized recycling system protects peroxiredoxin IV from
hyperoxidation. J. Biol. Chem. 289, 5490–5498 https://doi.org/10.1074/jbc.M113.529305
33 Kwak, G.-H., Kim, T.-H. and Kim, H.-Y. (2017) Down-regulation of MsrB3 induces cancer cell apoptosis through reactive oxygen species production and
intrinsic mitochondrial pathway activation. Biochem. Biophys. Res. Commun. 483, 468–474 https://doi.org/10.1016/j.bbrc.2016.12.120
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).838
Biochemical Journal (2018) 475 827–838
https://doi.org/10.1042/BCJ20170929
